 LAUSANNE, Switzerland, April 28, 2021 GLOBE NEWSWIRE -- AC Immune SA NASDAQ: ACIU, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the quarter ended March 31, 2021. The Company also provided an overview of its recent clinical and corporate highlights and anticipated milestones for 2021. 